Business Context and Reporting Period
This Form 8-K, filed on December 21, 2009, reports events occurring on December 19 and 20, 2009, for OncoGenex Pharmaceuticals, Inc. (the "Registrant") and its wholly-owned subsidiary, OncoGenex Technologies Inc. (the "Company"). The filing details a strategic partnership with Teva Pharmaceutical Industries Ltd. ("Teva") regarding the development and commercialization of OGX-011, a compound designed to inhibit clusterin production for cancer treatment.
Key Financial Metrics and Transaction Terms
The filing outlines a significant capital infusion and revenue structure rather than historical operating results.
- Up-Front Payments: Teva agreed to pay $50 million in up-front payments.
- Equity Investment: Teva agreed to purchase 267,531 shares of Registrant common stock for $10 million at $37.38 per share (a 20% premium to the 30-day average closing price).
- Milestone Payments: The Company is eligible for up to $370 million in additional payments upon achieving developmental and commercial milestones.
- Royalties: Teva will pay tiered royalties ranging from the mid-teens to mid-twenties on net sales.
- Net Proceeds: After deducting $10 million payable to Isis Pharmaceuticals, Inc. and approximately $517,000 to the University of British Columbia (UBC), the anticipated net proceeds to the Registrant and subsidiary are approximately $49.5 million.
- Development Costs: The Company is required to contribute $30 million in direct and indirect costs toward the clinical development plan, funded by the Teva up-front payment.
Material Changes and Agreements
The primary material change is the entry into a Collaboration and License Agreement and a Stock Purchase Agreement with Teva. Key terms include:
- Licensing Rights: Teva receives exclusive worldwide rights to develop and commercialize OGX-011. The Company retains an option to co-promote in the U.S. and Canada.
- Third-Party Obligations: The Company must pay 31% of non-sales-based milestone payments to third parties (Isis and UBC). Royalties to third parties on net sales are estimated between 4.88% and 8.00%.
- Clinical Development Plan (CDP): Three Phase III trials are planned:
- Second-line castrate resistant prostate cancer (initiation expected 2010).
- First-line castrate resistant prostate cancer (initiation expected 2010).
- First-line non-small cell lung cancer (initiation expected early 2011).
- Amendments: License agreements with Isis and UBC were amended to facilitate the Teva deal, including specific change-of-control provisions for Isis.
Outlook, Risks, and Contingencies
Management commentary focuses on the strategic value of the partnership to advance OGX-011. The filing includes standard forward-looking statements regarding the therapeutic potential and safety of the drug.
- Termination Rights: Teva may terminate the agreement after the completion of the three Phase III trials or upon material adverse changes in patent rights, safety issues, or "futility." Termination requires 3 months' notice prior to regulatory approval or 6 months' notice thereafter.
- Change of Control: If the Company undergoes a change of control, Teva may terminate the joint steering committee or co-promotion options. Specific milestone payments to Isis may be triggered depending on the nature of the change of control.
- Risks: The filing cautions that results may differ materially from projections due to risks inherent in drug discovery, development, and commercialization.
Investor Verification Checklist
- Verify the exact closing date and receipt of the $50 million up-front payment and $10 million equity investment.
- Confirm the specific regulatory milestones required to trigger the $370 million in potential payments.
- Review the full text of the Collaboration Agreement and Stock Purchase Agreement (expected as exhibits to the 2009 Form 10-K) for confidential treatment redactions.
- Monitor the initiation dates of the three Phase III clinical trials scheduled for 2010 and 2011.
- Assess the impact of the $30 million development cost obligation on the Company's cash runway post-transaction.